Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
In the latest session, Resmed Inc (NYSE: RMD) closed at $242.58 up 0.88% from its previous closing price of $240.46. In other words, the price has increased by $0.88 from its previous closing price. On the day, 1.0 million shares were traded. RMD stock price reached its highest trading level at $245.57 during the session, while it also had its lowest trading level at $240.46.
Ratios:
For a deeper understanding of Resmed Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 68.26 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 25.60. For the most recent quarter (mrq), Quick Ratio is recorded 2.29 and its Current Ratio is at 3.33. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.15.
On January 10, 2025, Piper Sandler started tracking the stock assigning a Neutral rating and target price of $252.
On December 13, 2024, Stifel started tracking the stock assigning a Hold rating and target price of $250.Stifel initiated its Hold rating on December 13, 2024, with a $250 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Feb 05 ’25 when FARRELL PETER C bought 2,000 shares for $250.00 per share.
FARRELL PETER C sold 2,000 shares of RMD for $484,220 on Feb 05 ’25. The Director now owns 77,218 shares after completing the transaction at $242.11 per share. On Feb 03 ’25, another insider, Rider Michael J, who serves as the Global General Counsel of the company, sold 64 shares for $242.42 each. As a result, the insider received 15,515 and left with 8,974 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RMD now has a Market Capitalization of 35626999808 and an Enterprise Value of 38229590016. As of this moment, Resmed’s Price-to-Earnings (P/E) ratio for their current fiscal year is 28.66, and their Forward P/E ratio for the next fiscal year is 23.18. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.03. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.23 while its Price-to-Book (P/B) ratio in mrq is 6.78. Its current Enterprise Value per Revenue stands at 7.952 whereas that against EBITDA is 23.422.
Stock Price History:
The Beta on a monthly basis for RMD is 0.74, which has changed by 0.30862582 over the last 52 weeks, in comparison to a change of 0.208081 over the same period for the S&P500. Over the past 52 weeks, RMD has reached a high of $263.05, while it has fallen to a 52-week low of $170.56. The 50-Day Moving Average of the stock is 0.80%, while the 200-Day Moving Average is calculated to be 6.80%.
Shares Statistics:
For the past three months, RMD has traded an average of 872.01K shares per day and 1310490 over the past ten days. A total of 146.86M shares are outstanding, with a floating share count of 145.80M. Insiders hold about 0.72% of the company’s shares, while institutions hold 61.56% stake in the company. Shares short for RMD as of 1736899200 were 8040958 with a Short Ratio of 9.22, compared to 1734048000 on 7806232. Therefore, it implies a Short% of Shares Outstanding of 8040958 and a Short% of Float of 6.3.
Dividends & Splits
The stock’s 5-year Average Dividend Yield is 0.83. The current Payout Ratio is 27.75% for RMD, which recently paid a dividend on 2024-11-07 with an ex-dividend date of 1739404800. Stock splits for the company last occurred on 2010-08-31 when the company split stock in a 2:1 ratio.
